Litigation Details for AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc. (N.D. Cal. 2016)

AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc. (N.D. Cal. 2016)

Docket		Date Filed	2016-01-26
Court	District Court, N.D. California	Date Terminated	2016-07-22
Cause	15:1 Antitrust Litigation	Assigned To	William Haskell Alsup
Jury Demand	Plaintiff	Referred To
Parties	GREGG S. GONSALVES, PHD; JACOB ZYDONIS; JANSSEN SCIENCES IRELAND UC
Patents	6,642,245; 6,703,396; 7,390,791; 7,635,704; 7,800,788; 7,803,788; 8,148,374; 8,633,219; 8,754,065; 8,981,103
Attorneys	Jerome W Hoffman; Matthew H Dawson; Thomas Andrew Myers
Firms	Fitzpatrick, Cella, Harper & Scinto; Irell & Manella LLP
Link to Docket	External link to docket

Details for AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc. (N.D. Cal. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2016-01-25	1	Complaint	10  U.S. Patent No. 6,642,245, entitled “Antiviral activity and resolution…years before Gilead obtained a patent on TAF, Gilead 11 had patented a similar prodrug called Tenofovir…weakness of the patents covering TAF, Gilead illegally seeks to 13 extend the period of patent exclusivity… The patents on TDF expire in 2017 and 2018. The impending expiration of the 23 TDF patents presented…was heavily reliant on the patent 24 exclusivity period of the TDF patents to prevent entry by generic	External link to document
2016-07-06	108	Order on Motion to Dismiss	12 7,390,791 — “Prodrugs of phosphonate nucleotide Gilead … 9 patents (regardless of the patent owner) that it believes cover the … until the patent expires (if it has not already expired) or by stating that the patent is invalid or… constitutes an artificial act of patent infringement. If the patent owner initiates … PATENT PATENT OWNER	External link to document
2016-03-21	34	Motion to Dismiss	any of the patents identified in Count 1 of the Complaint including U.S. Patent No. 8,633,219.3 1n sum,…not JTI USA_as the owner of U.S. Patent No. 8,633,219 (the “‘219 Patent”). Nowhere is J T1 USA_identified…embodies a patent exhausts the patent holder’s rights and prevents the patent holder from invoking patent law…Exhibit C at p. 1. The official patent, obtained from the United States Patent and Trademark Office, clearly…alleged) that it has any. ‘219 Patent. The remaining patents set forth in the Complaint are alleged	External link to document
2016-03-21	35	Request for Judicial Notice	B - Gilead Form 10-K, # 3 Exhibit C - U.S. Patent 8,633,219)(Related document(s) 34 ) (Hoffman, Jerome	External link to document
2016-04-11	50	Amended Complaint	enter a declaration that United States Patent Nos. 7,390,791; 14 7,800,788; 8,754,065; 8,148,374…  U.S. Patent No. 7,390,791, entitled “Prodrugs of phosphonate 21 …that enjoy the patent protections of not only 15 the TAF patents, but also the patents that cover the…years before Gilead obtained a patent on TAF, Gilead 11 had patented a similar prodrug called Tenofovir…weakness of the patents covering TAF, Gilead illegally seeks to 13 extend the period of patent exclusivity	External link to document
2016-06-16	93	Case Management Statement	multiple patents covering TAF products, including U.S. Patent Nos. 3 7,390,791, 7,803,… Plaintiff contends that U.S. Patent Nos. 7,390,791; 7,800,788; 8,754,065; 8,148,374; and …Plaintiff seeks (1) a declaration that U.S. Patent Nos. 7,390,791; 7,800,788; 8,754,065; 26 … and 8,754,065. The Patent Office also granted Gilead 4 patents covering emtricitabine… 9 the patents identified in Count I of the Amended Complaint, particularly the ‘219 Patent.	External link to document